Navigation Links
Grove Gift Launches Translational Medicine Program at UCSF & UC Berkeley
Date:5/20/2010

Former Intel Corp. chief executive Andy Grove has pledged $1.5 million to two University of California campuses -- San Francisco and Berkeley -- to jointly launch the first program of its kind aimed at accelerating the translation of cutting-edge research into advances in patient care.

(Vocus) May 20, 2010 -- Former Intel Corp. chief executive Andy Grove has pledged $1.5 million to two University of California campuses -- San Francisco and Berkeley -- to jointly launch the first program of its kind aimed at accelerating the translation of cutting-edge research into advances in patient care.

The commitment, which the two campuses will share equally, will enable UCSF and UC Berkeley to create a combined program in translational medicine at the master’s level. The program aims to address the critical need for expediting new therapies to treat devastating diseases such as cancer, neurological disorders and diabetes.

“The significance of this gift is that it reflects Andy’s powerful vision of infusing the spirit of Silicon Valley innovation into the advancement of patient therapies and care,” said UCSF Chancellor Susan Desmond-Hellmann, MD, MPH.

The two-year program was the brainchild of Grove, who believes that the model which has fueled innovation in technology can do the same in health care.

”What we have learned from decades of rapid development of information technology is that the key is relentless focus on ‘better, faster, cheaper’ -- in everything,” Grove said. “The best results are achieved through the cooperative efforts of different disciplines, all aimed at the same objective.”

Despite the nearly $30 billion annual investment in federal research funding through the National Institutes of Health, there has been increasing concern that these investments have not resulted in the expected cures for life-threatening diseases. In fact, while inflation-adjusted federal research spending doubled from 1995 to 2005, new drug approvals were flat, said S. Claiborne “Clay” Johnston, MD, PhD, associate vice chancellor of research at UCSF and the director of the UCSF Clinical and Translational Science Institute, which helped launch the program and will assist in its oversight.

“We see this program filling an important gap,” Johnston said. “Clinicians generally don’t have the skills to be good inventors, and engineers often don’t understand the clinical problems. Our program is trying to provide pivotal training to both groups.”

The program’s placement in the San Francisco Bay Area, amidst the innovation of both the nation’s largest biotechnology hub and Silicon Valley, also will enable students to learn from the collaborations and synergies that propelled both the high-tech and biotech industries, Johnston said.

Matthew Tirrell, PhD, chair of the UC Berkeley bioengineering department, who will co-direct the new program along with UCSF bioengineering professor Tejal Desai, PhD, said the two campuses had been discussing the possibility of such a program to tackle this growing area of concern before Grove outlined his idea during a November 2009 conference at UCSF. That, Tirrell said, gave both UC campuses the inspiration, focus and now funding, to bring this to fruition.

“Engineers are, by nature, interested in translational -- or applied -- research, whether that’s in developing a safer airplane or using nano-technology to improve health,” Tirrell said. “The close ties between UC Berkeley and UCSF in bioengineering and research, as well as our history of cooperation, make this the ideal environment for using that engineering expertise to apply that approach to medicine.”

Engineers and bioengineers already are involved in many aspects of healthcare, from developing new ways to deliver therapeutics, to designing medical devices, equipment and consumer-related healthcare products that can improve patients’ self-reliance.

The program will begin this fall with roughly a dozen students and initially will be offered through the existing master’s program in the UCSF-UC Berkeley Joint Graduate Group in Bioengineering, which is a cooperative venture between the UC Berkeley Department of Bioengineering and the UCSF Department of Bioengineering and Therapeutic Sciences.

It will be patterned on a model of a master’s of business administration, teaching the critical-thinking skills needed to maneuver through the many obstacles along the route from laboratory bench to patient bedside, and will draw a student body from a diverse array of backgrounds, including engineering, bioengineering, business, medicine, basic research and industry. The program will complement those backgrounds, while giving students hands-on experience in multidisciplinary projects to tackle a specific obstacle in the field.

The program is unique in both offering a professional degree and in integrating the perspectives of a broad field of backgrounds, Johnston said. As this grows to an expected 50 students per year over the next six years, the graduate group intends to request approval from the UC Office of the President to make it an independent master’s degree program, rather than a subset of bioengineering.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. For further information, visit www.ucsf.edu.

UC Berkeley was established in 1868 as the first of today’s 10-campus University of California system. Today ranking among the nation’s preeminent public research universities and a wellspring of innovation, UC Berkeley’s faculty, students, and alumni make key contributions to the economic and social well-being of the Bay Area, California, and the nation. For further information, visit berkeley.edu.

Links:

Webcast of Nov. 18 conference: http://coe.berkeley.edu/static/streaming/gtl-conference/2009/
CTSI: The Clinical and Translational Science Institute at UCSF
UCSF: www.ucsf.edu
UC Berkeley College of Engineering: http://coe.berkeley.edu/
Follow UCSF on Twitter at http://twitter.com/ucsfnews

###

Read the full story at http://www.prweb.com/releases/translational/medicine/prweb4030604.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
2. Novozymes Launches Enzyme to Reduce Acrylamide in Food
3. Enova Medical Launches Exos Corporation
4. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
5. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
6. ThirdBiotech Networking Group Launches
7. BioReliance Launches Next-Generation Genotoxicity Screening Service
8. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
9. BioReliance Corporation Launches iNet(TM) for Online Results Tracking of Biological Safety Tests
10. Kingfisher Healthcare Launches Breakthrough Product in Europe
11. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Grove Gift Launches Translational Medicine Program at UCSF & UC Berkeley 
(Date:2/24/2017)... Feb. 24, 2017 Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... to participate in its previously announced rights offering ... shares of common stock and Series C Convertible ... listed warrants. As previously announced, ...
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Blood Corporation (NYSE: CO ) ("CCBC" or ... laboratory testing, hematopoietic stem cell processing and stem cell ... the third quarter and first nine months of fiscal ... Quarter of Fiscal 2017 Highlights Revenues ... 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), ... announced its financial results for the fourth quarter and fiscal ... Highlights Total sales in the fourth ... increased by 13.6% in USD terms to $77.6 million from ... Gross profit increased by 13.3% to $46.8 million from ...
Breaking Biology Technology:
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special Counsel to ... of Identity Strategy Partners, LLP, today releases the following ... Protecting the Nation From Foreign Terrorist Entry Into the ... Trump,s ,Travel Ban, Executive Order gains more notoriety and ... ban, it is important that our national discourse regain ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
Breaking Biology News(10 mins):